Acadia Pharmaceuticals (ACAD)

• Market cap: $4.59B
• 1 day: 1.31%
• 5 days: 1.8%
• 1 month: 13.08%
• 3 months: 12.19%
• 6 months: 19.08%
• Year to date: 45.5%
• 1 year: 55.94%
• 5 years: -50.82%
• 10 years: -21.26%
• Sector: Healthcare
• Industry: Biotechnology

About: Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Employees: 654